Expressions of concern about prescription drug prices and prescription drug spending are widespread. Among the product classes that have drawn attention is oncology. New oncology therapies exhibit a typical life cycle of changing sales over time, particularly when generics enter the market. As patents expire, expenditures on oncology therapies will be affected. This policy brief examines the life cycle of four specific oncology therapies.